Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker WGS
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 5,410 | $458.5K | — | Sep 1, 2026 | Form 4 ↗ 2 days later · 372 shares | Form 144 ↗ |
| Sep 1, 2026 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 14,243 | $1.2M | — | Sep 9, 2026 | Form 4 ↗ 10 days later · 3,692 shares | Form 144 ↗ |
| Apr 29, 2026 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 5,804 | $366.0K | — | Apr 29, 2026 | Form 4 ↗ 2 days later · 392 shares | Form 144 ↗ |
| Apr 29, 2026 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 16,415 | $1.0M | — | Apr 29, 2026 | Form 4 ↗ 2 days later · 2,172 shares | Form 144 ↗ |
| Feb 2, 2026 | Bryan Dechairo Officer | WGS GeneDx Holdings Corp. | 9,374 | $929.9K | 10b5-1 | Feb 2, 2026 | Form 4 ↗ 1 day later · 3,413 shares | Form 144 ↗ |
| Jan 29, 2026 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 24,155 | $2.4M | — | Jan 29, 2026 | Form 4 ↗ 4 days later · 317 shares | Form 144 ↗ |
| Jan 29, 2026 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 94,495 | $9.3M | — | Jan 29, 2026 | Form 4 ↗ 4 days later · 1,653 shares | Form 144 ↗ |
| Nov 24, 2025 | Joshua Ruch Director | WGS GeneDx Holdings Corp. | 38,000 | $6.1M | — | Nov 24, 2025 | Form 4 ↗ 2 days later · 38,000 shares | Form 144 ↗ |
| Sep 30, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 6,609 | $716.3K | 10b5-1 | Sep 30, 2025 | Form 4 ↗ 1 day later · 6,609 shares | Form 144 ↗ |
| Sep 30, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 5,805 | $625.4K | 10b5-1 | Sep 30, 2025 | Form 4 ↗ 1 day later · 6,609 shares | Form 144 ↗ |
| Sep 30, 2025 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 12,858 | $1.4M | 10b5-1 | Sep 30, 2025 | Form 4 ↗ 1 day later · 12,858 shares | Form 144 ↗ |
| Sep 30, 2025 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 16,425 | $1.8M | 10b5-1 | Sep 30, 2025 | Form 4 ↗ 1 day later · 12,858 shares | Form 144 ↗ |
| Aug 27, 2025 | Ryan Jason Director | WGS GeneDx Holdings Corp. | 39,222 | $5.0M | — | Aug 27, 2025 | Form 4 ↗ same day · 39,222 shares | Form 144 ↗ |
| Aug 22, 2025 | Casdin Partners Master Fund, L.P. Affiliate | WGS GeneDx Holdings Corp. | 500,000 | $60.5M | — | Aug 22, 2025 | Form 4 ↗ same day · 500,000 shares | Form 144 ↗ |
| Jul 1, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 6,622 | $613.3K | 10b5-1 | Jul 1, 2025 | Form 4 ↗ 2 days later · 1,344 shares | Form 144 ↗ |
| Jul 1, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 5,805 | $535.9K | 10b5-1 | Jul 1, 2025 | Form 4 ↗ 2 days later · 1,344 shares | Form 144 ↗ |
| Jul 1, 2025 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 12,877 | $1.2M | 10b5-1 | Jul 1, 2025 | Form 4 ↗ 2 days later · 9,657 shares | Form 144 ↗ |
| Jul 1, 2025 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 16,425 | $1.5M | 10b5-1 | Jul 1, 2025 | Form 4 ↗ 2 days later · 9,657 shares | Form 144 ↗ |
| Jun 9, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 5,009 | $363.4K | — | Jun 9, 2025 | Form 4 ↗ 2 days later · 1,266 shares | Form 144 ↗ |
| Jun 9, 2025 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 14,139 | $1.0M | — | Jun 9, 2025 | Form 4 ↗ 2 days later · 3,639 shares | Form 144 ↗ |
| Jun 2, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 370 | $26.4K | — | Jun 2, 2025 | Form 4 ↗ 1 day later · 370 shares | Form 144 ↗ |
| Apr 29, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 388 | $43.9K | — | Apr 29, 2025 | Form 4 ↗ 2 days later · 388 shares | Form 144 ↗ |
| Apr 29, 2025 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 2,154 | $243.6K | — | Apr 29, 2025 | Form 4 ↗ 2 days later · 2,154 shares | Form 144 ↗ |
| Apr 14, 2025 | Icahn School of Medicine At Mount Sinai Stockholder | WGS GeneDx Holdings Corp. | 250,000 | $25.3M | — | Apr 14, 2025 | — | Form 144 ↗ |
| Apr 14, 2025 | Icahn School of Medicine At Mount Sinai Stockholder | WGS GeneDx Holdings Corp. | 250,000 | $25.3M | — | Apr 14, 2025 | — | Form 144 ↗ |
| Apr 9, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 14,270 | $1.3M | 10b5-1 | Apr 9, 2025 | Form 4 ↗ 1 day later · 15,516 shares | Form 144 ↗ |
| Apr 9, 2025 | Katherine Stueland Officer | WGS GeneDx Holdings Corp. | 46,594 | $4.1M | 10b5-1 | Apr 9, 2025 | Form 4 ↗ 1 day later · 46,594 shares | Form 144 ↗ |
| Mar 26, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 8,746 | $836.2K | — | Mar 26, 2025 | Form 4 ↗ 2 days later · 8,746 shares | Form 144 ↗ |
| Mar 26, 2025 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 46,551 | $4.5M | — | Mar 26, 2025 | Form 4 ↗ 2 days later · 46,551 shares | Form 144 ↗ |
| Mar 17, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 3,749 | $362.6K | — | Mar 17, 2025 | Form 4 ↗ same day · 3,749 shares | Form 144 ↗ |
| Mar 17, 2025 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 10,559 | $1.0M | — | Mar 17, 2025 | Form 4 ↗ same day · 10,559 shares | Form 144 ↗ |
| Mar 13, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 402 | $36.2K | — | Mar 13, 2025 | Form 4 ↗ 4 days later · 4,151 shares | Form 144 ↗ |
| Mar 13, 2025 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 1,078 | $96.4K | — | Mar 13, 2025 | Form 4 ↗ 4 days later · 11,637 shares | Form 144 ↗ |
| Mar 10, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 922 | $87.3K | — | Mar 10, 2025 | Form 4 ↗ 1 day later · 922 shares | Form 144 ↗ |
| Mar 10, 2025 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 2,731 | $258.7K | — | Mar 10, 2025 | Form 4 ↗ 1 day later · 2,731 shares | Form 144 ↗ |
| Mar 3, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 261 | $27.1K | — | Mar 3, 2025 | Form 4 ↗ 1 day later · 261 shares | Form 144 ↗ |
| Feb 24, 2025 | Icahn School of Medicine At Mount Sinai Stockholder | WGS GeneDx Holdings Corp. | 373,569 | $35.8M | — | Feb 24, 2025 | — | Form 144 ↗ |
| Feb 24, 2025 | Icahn School of Medicine At Mount Sinai Stockholder | WGS GeneDx Holdings Corp. | 373,569 | $35.8M | — | Feb 24, 2025 | — | Form 144 ↗ |
| Jan 30, 2025 | Icahn School of Medicine At Mount Sinai Stockholder | WGS GeneDx Holdings Corp. | 1.35M | $104.8M | — | Jan 30, 2025 | — | Form 144 ↗ |
| Jan 30, 2025 | Icahn School of Medicine At Mount Sinai Stockholder | WGS GeneDx Holdings Corp. | 1.35M | $104.8M | — | Jan 30, 2025 | — | Form 144 ↗ |
| Jan 29, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 275 | $21.6K | — | Jan 29, 2025 | Form 4 ↗ 2 days later · 275 shares | Form 144 ↗ |
| Jan 29, 2025 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 1,657 | $130.0K | — | Jan 29, 2025 | Form 4 ↗ 2 days later · 1,657 shares | Form 144 ↗ |
| Jan 7, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 35,506 | $3.3M | 10b5-1 | Jan 7, 2025 | Form 4 ↗ 3 days later · 35,506 shares | Form 144 ↗ |
| Jan 7, 2025 | Katherine Stueland Officer | WGS GeneDx Holdings Corp. | 51,420 | $4.8M | 10b5-1 | Jan 7, 2025 | Form 4 ↗ 3 days later · 51,420 shares | Form 144 ↗ |
| Jan 2, 2025 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 1,430 | $108.0K | 10b5-1 | Jan 2, 2025 | Form 4 ↗ 4 days later · 1,430 shares | Form 144 ↗ |
| Jan 2, 2025 | Katherine Stueland Officer | WGS GeneDx Holdings Corp. | 18,006 | $1.4M | 10b5-1 | Jan 2, 2025 | Form 4 ↗ 4 days later · 18,006 shares | Form 144 ↗ |
| Dec 16, 2024 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 3,728 | $286.1K | — | Dec 16, 2024 | Form 4 ↗ 2 days later · 3,728 shares | Form 144 ↗ |
| Dec 16, 2024 | Katherine Stueland Officer, Director | WGS GeneDx Holdings Corp. | 10,501 | $806.0K | — | Dec 16, 2024 | Form 4 ↗ 2 days later · 10,501 shares | Form 144 ↗ |
| Dec 9, 2024 | Kevin Feeley Officer | WGS GeneDx Holdings Corp. | 1,137 | $86.8K | — | Dec 9, 2024 | Form 4 ↗ 2 days later · 1,137 shares | Form 144 ↗ |
| Dec 9, 2024 | Katherine Stueland Director, Officer | WGS GeneDx Holdings Corp. | 3,661 | $279.6K | — | Dec 9, 2024 | Form 4 ↗ 2 days later · 3,661 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 6:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances